Scholarlink

Background <p>Primary membranoproliferative glomerulonephritis (MPGN) is a rare progressive kidney disease that often leads to end-stage kidney disease. Our previous nationwide registry study (Report 1, 2015–2018) characterized initial demographics and treatment patterns. In this study (Report 2), we aimed to update these findings, focusing on newly registered cases (2017–2021).</p> Methods <p>Personal clinical records of patients with primary MPGN between 2017 and 2021 were obtained from the national registry organized by the Japanese Ministry of Health, Labour and Welfare. Characteristics of primary MPGN throughout Japan were investigated.</p> Results <p>A total of 210 patients (median age, 49&#xa0;years; male, 51%) with newly registered primary MPGN were identified. Nephrotic syndrome was present in 83.8% of patients at enrollment. Initial treatment frequently included corticosteroids (63.8%), with a modest increase in intravenous methylprednisolone pulse therapy (41.4%) compared with that in Report 1. The incidence of hemodialysis was 7.1%. Compared with those in Report 1, the demographic patterns were similar; however, nephrotic presentations were more common. Cyclosporine and mizoribine usage were significantly higher in the pediatric group (&lt; 18&#xa0;years, <i>n</i> = 44) compared to the corresponding usage in the older adult group (≥ 65&#xa0;years, <i>n</i> = 75). The mean dosage of oral prednisolone and other immunosuppressants during initial treatment did not differ among the four age groups.</p> Conclusion <p>Compared with the earlier report (Report 1), patients with newly registered primary MPGN presented with nephrotic syndrome more often, highlighting the continued risk of poor prognosis and the need for more refined therapeutic approaches.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Initial treatment patterns of primary membranoproliferative glomerulonephritis in Japan (2017–2021): an updated analysis based on nationwide personal clinical records

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月15日

查看全文
  • Naoki Nakagawa,
  • Keiju Hiromura,
  • Yoshitaka Isaka

摘要

Background

Primary membranoproliferative glomerulonephritis (MPGN) is a rare progressive kidney disease that often leads to end-stage kidney disease. Our previous nationwide registry study (Report 1, 2015–2018) characterized initial demographics and treatment patterns. In this study (Report 2), we aimed to update these findings, focusing on newly registered cases (2017–2021).

Methods

Personal clinical records of patients with primary MPGN between 2017 and 2021 were obtained from the national registry organized by the Japanese Ministry of Health, Labour and Welfare. Characteristics of primary MPGN throughout Japan were investigated.

Results

A total of 210 patients (median age, 49 years; male, 51%) with newly registered primary MPGN were identified. Nephrotic syndrome was present in 83.8% of patients at enrollment. Initial treatment frequently included corticosteroids (63.8%), with a modest increase in intravenous methylprednisolone pulse therapy (41.4%) compared with that in Report 1. The incidence of hemodialysis was 7.1%. Compared with those in Report 1, the demographic patterns were similar; however, nephrotic presentations were more common. Cyclosporine and mizoribine usage were significantly higher in the pediatric group (< 18 years, n = 44) compared to the corresponding usage in the older adult group (≥ 65 years, n = 75). The mean dosage of oral prednisolone and other immunosuppressants during initial treatment did not differ among the four age groups.

Conclusion

Compared with the earlier report (Report 1), patients with newly registered primary MPGN presented with nephrotic syndrome more often, highlighting the continued risk of poor prognosis and the need for more refined therapeutic approaches.